Fredun Pharmaceuticals Ltd — Important, 25-02-2026: Company Update

Fredun Pharmaceuticals secured a credit rating upgrade from Infomerics for its ₹156.17 crore bank facilities. The long-term rating improved to IVR BBB+ (Stable) from IVR BBB (Stable), while the short-term rating was reaffirmed at IVR A2. This reflects the company's improved operational performance, stronger financial profile, and disciplined capital management over FY24 and FY25. For shareholders, this upgrade signals enhanced credit quality, improved financial flexibility to support expansion, and potential optimization of borrowing costs, strengthening its growth prospects.